eli lilly phase 3 trial retatrutide ESC 2024: improves lipid and cardiovascular risk profile in II Today, we shared new data
Description
Obesity is also a leading driver of gastrointestinal (GI) and hepatobiliary cancers, from colorectal cancer to hepatocellular carcinoma, making any therapy that modifies obesity-related cancer risk directly relevant to gastroenterology practice
Persistent bleeding, especially if it is heavy or accompanied by other symptoms
Questions to Ask Your Doctor Given my weight loss goals, is a GLP-1 a good fit for me
Paid subscriptions are voluntary and of course appreciated
Does insulin explain the relation between maternal obesity and poor lactation outcomes
